Menu Search
Equities

Alvotech SA

ALVO:NMQ

Alvotech SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.94
  • Today's Change-0.50 / -4.02%
  • Shares traded31.48k
  • 1 Year change+30.85%
  • Beta-0.1145
Data delayed at least 15 minutes, as of Nov 22 2024 15:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Alvotech SA had net income fall 7.43% from a loss of 513.58m to a larger loss of 551.73m despite a 9.84% increase in revenues from 85.02m to 93.38m. An increase in the cost of goods sold as a percentage of sales from 75.39% to 172.26% was a component in the falling net income despite rising revenues.
Gross margin59.03%
Net profit margin-112.07%
Operating margin-28.40%
Return on assets-40.28%
Return on equity--
Return on investment-47.87%
More ▼

Cash flow in USDView more

In 2024, Alvotech SA increased its cash reserves by 960.09%, or 107.12m. Cash Flow from Financing totalled 293.01m or 86.53% of revenues. In addition the company used 197.64m for operations while cash used for investing totalled .
Cash flow per share-1.63
Price/Cash flow per share--
Book value per share-1.29
Tangible book value per share-1.41
More ▼

Balance sheet in USDView more

Alvotech SA has a Debt to Total Capital ratio of 141.07%.
Current ratio2.69
Quick ratio1.92
Total debt/total equity--
Total debt/total capital1.41
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.